Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
VRE bloodstream or endovascular infection
Sepsis with vancomycin-resistant Enterococcus in blood, especially with a central line, abdominal source, prosthetic valve or persistent cultures, carries high risk of treatment delay and metastatic infection.
Action: Use ABCDE and sepsis care, repeat cultures, start susceptibility-directed linezolid or high-dose daptomycin with infection and microbiology input, remove or control the source, evaluate for endocarditis, and apply IPC precautions.
Synopsis
Distinguish intestinal or urinary carriage from invasive vancomycin-resistant enterococcal disease, obtain cultures and source control, select species- and susceptibility-directed therapy, and contain healthcare transmission without ineffective decolonisation.
Enterococci normally colonise the bowel. VRE or glycopeptide-resistant enterococci are usually E. faecium carrying vanA or vanB, although other species and intrinsic resistance occur.
A positive rectal screen, stool culture, chronic wound or asymptomatic catheter urine usually represents carriage and does not require systemic antibiotic treatment.
Bloodstream isolation is always significant. Obtain cultures before treatment when safe, repeat until clearance and identify central-line, biliary, urinary, abdominal, valve or prosthetic sources.
Key red flags
Persistent blood-culture positivity beyond 48 to 72 hours on active therapy suggests retained line, undrained abdominal source, infected thrombus, endocarditis or inadequate exposure.
Bloodstream infection
Fever, rigors, hypotension or organ dysfunction with VRE in blood is invasive disease, often arising from a line or gastrointestinal source.
Investigation priorities
01
First-line blood culturesFirst stepFirst line
Confirm invasive infection, evaluate sepsis and provide the clearance date that informs duration.
Management branches
COLONISATIONDecide whether treatment is needed
VRE is reported from screening, urine, wound, drain or another clinical specimen.
Examine for local inflammation and systemic illness, identify the specimen quality and ask whether another organism or non-infectious cause better explains the presentation.
Do not treat a rectal screen, asymptomatic bacteriuria or colonised wound; remove unnecessary urinary or vascular devices and improve wound containment.
Key medicines
LinezolidGive 600 mg orally or intravenously every 12 hours; use the same dose after oral conversion because bioavailability is near complete.
High-dose daptomycinGive 10 to 12 mg/kg intravenously every 24 hours for serious VRE bacteraemia or endovascular infection under specialist off-label governance, with renal interval adjustment.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.